| Naloxone dosage for opioid reversal: current evidence and clinical implications |
39 |
| Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine |
25 |
| The risks of long-term use of proton pump inhibitors: a critical review |
19 |
| An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine |
13 |
| Using EMR-enabled computerized decision support systems to reduce prescribing of potentially inappropriate medications: a narrative review |
12 |
| Precision medicine: does ethnicity information complement genotype-based prescribing decisions? |
12 |
| Smoking cessation in pregnancy: a continuing challenge in the United States |
11 |
| Explicit criteria as clinical tools to minimize inappropriate medication use and its consequences |
10 |
| Poly-de-prescribing to treat polypharmacy: efficacy and safety |
9 |
| Principle of rational prescribing and deprescribing in older adults with multiple chronic conditions |
8 |
| Adverse events associated with home use of mouthrinses: a systematic review |
7 |
| Interventions to reduce medication errors in neonatal care: a systematic review |
7 |
| Medication use and potentially inappropriate prescribing in older adults with intellectual disabilities: a neglected area of research |
7 |
| Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence |
7 |
| Incident adverse drug reactions in geriatric inpatients: a multicentred observational study |
6 |
| Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety |
6 |
| Deprescribing conversations: a closer look at prescriber-patient communication |
6 |
| Abuse potential of mirogabalin in recreational polydrug users |
5 |
| Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy |
5 |
| Evaluation of methenamine for urinary tract infection prevention in older adults: a review of the evidence |
5 |
| Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: a systematic review |
5 |
| Integration of an electronic Drug Burden Index risk assessment tool into Home Medicines Reviews: deprescribing anticholinergic and sedative medications |
5 |
| Feasibility, acceptability and potential effectiveness of an information technology-based, pharmacist-led intervention to prevent an increase in anticholinergic and sedative load among older community-dwelling individuals |
4 |
| Benefit-risk evaluation: the past, present and future |
4 |
| Bisphosphonates and cardiovascular risk in elderly patients with previous cardiovascular disease: a population-based nested case-control study in Italy |
4 |
| Medication appropriateness criteria for older adults: a narrative review of criteria and supporting studies |
4 |
| Trigger alerts associated with laboratory abnormalities on identifying potentially preventable adverse drug events in the intensive care unit and general ward |
4 |
| Clinical practice guidelines for older people with multimorbidity and life-limiting illness: what are the implications for deprescribing? |
4 |
| Pharmacist-assisted electronic prescribing at the time of admission to an inpatient orthopaedic unit and its impact on medication errors: a pre- and postintervention study |
4 |
| The surge in biosimilars: considerations for effective pharmacovigilance and EU regulation |
3 |
| Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada |
3 |
| Spontaneously reported adverse drug events related to tapentadol and oxycodone/naloxone in Australia |
3 |
| Variability in the clinical management of iron deficiency anaemia in older adults: results from a survey of UK specialists in the care of older people |
3 |
| Polypills for the secondary prevention of cardiovascular disease: effective in improving adherence but are they safe? |
3 |
| Contemporary utilization of antithrombotic therapy for stroke prevention in patients with atrial fibrillation: an audit in an Australian hospital setting |
3 |
| Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation |
3 |
| Likelihood of reporting medication errors in hospitalized children: a survey of nurses and physicians |
3 |
| Impact of dextrose dose on hypoglycemia development following treatment of hyperkalemia |
3 |
| Metformin treatment of type 2 diabetes mellitus in pregnancy: update on safety and efficacy |
3 |
| Shed-MEDS: pilot of a patient-centered deprescribing framework reduces medications in hospitalized older adults being transferred to inpatient postacute care |
3 |
| Educational intervention to improve the knowledge, attitude and practice of healthcare professionals regarding pharmacovigilance in South-South Nigeria |
3 |
| 'I think this medicine actually killed my wife': patient and family perspectives on shared decision-making to optimize medications and safety |
2 |
| Case series of docetaxel-induced dorsal hand-foot syndrome |
2 |
| Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty |
2 |
| Applicability of EU(7)-PIM criteria in cross-national studies in European countries |
2 |
| Ceftolozane-tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series |
2 |
| How Clinical Practice Research Datalink data are used to support pharmacovigilance |
2 |
| Influence of stroke and bleeding risk on prescribing of oral anticoagulants in older inpatients; has the availability of direct oral anticoagulants changed prescribing? |
2 |
| Pharmacovigilance of medicines for rare and ultrarare diseases |
2 |
| Strategies to promote public engagement around deprescribing |
2 |
